TRICARE may cover gender-affirming hormone therapy for individuals diagnosed with gender dysphoria
People are filing Ozempic lawsuits alleging they developed unexpected and severe side effects from the drug, which is also called semaglutide
Disclosures: Yousif Alyousifi: Nothing to Disclose, Chinmay Raut: Nothing to Disclose, Antonino Oliveri: Nothing to Disclose, Vincent Chen: AstraZeneca: site PI on industry-sponsored trial, Ipsen: site co-I on industry-sponsored trial, Kowa: site co-I on industry-sponsored trial, Elizabeth Speliotes: Nothing to Disclose 2562 DEVELOPMENT OF MUTATED B-CATENIN GENE SIGNATURE (MBGS) TO IDENTIFY CTNNB1 MUTATIONS FROM WHOLE AND SPATIAL TRANSCRIPTOMIC DATA IN PATIENTS Brandon Lehrich 1 Junyan Tao 1 Silvia Liu 1 Theo Hirsch 2 Tyler Yasaka 1 Catherine Cao 1 Evan Delgado 1 Yuqing Liu 1 Xiangnan Guan 3 Shan Lu 3 Long Pan 2 Sucha Singh 1 Minakshi Poddar 1 Aatur Singhi 4 Jessica Zucman-Rossi 5 Yulei Wang 3 Satdarshan (Paul) Monga 1 , 1 University of Pittsburgh, 2 Centre de Recherche des Cordeliers, Universit Paris Cit, Sorbonne Universit, Inserm, F-75006 Pari, 3 Translational Medicine, Genentech Inc., San Francisco, CA, USA, 4 Department of Pathology, UPMC, 5 French Institute of Health and Medical Research/Inserm Background: Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-related death
doi: 10.2337/db14-0302 37 BurmeisterMAAyalaJDruckerDJAyalaJE
